Follicular Lymphoma Therapeutics
1. Tazverik patent expiration
Treatment: Method of treating a lung metastasis of epithelioid sarcoma; Method of treating relapsed or refractory follicular lymphoma; Method of treati...
TAZVERIK's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9394283 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US11052093 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9090562 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168015 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US8410088 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Jan, 2034
(8 years from now) | |
| US10821113 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9872862 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US9522152 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Apr, 2032
(6 years from now) | |
| US9889138 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US8765732 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9549931 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9334527 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9333217 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8691507 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9175331 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US8895245 | EPIZYME INC | Inhibitors of human EZH2 and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US9949999 | EPIZYME INC | Inhibitors of human EZH2, and methods of use thereof |
Sep, 2031
(5 years from now) | |
| US10369155 | EPIZYME INC | Method for treating cancer |
Oct, 2035
(9 years from now) | |
| US10420775 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US12168014 | EPIZYME INC | Method for treating cancer |
May, 2038
(12 years from now) | |
| US12162865 | EPIZYME INC | Methods of treating cancer |
Jun, 2034
(8 years from now) | |
| US12168016 | EPIZYME INC | Aryl-OR heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10155002 | EPIZYME INC | Aryl- or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US9688665 | EPIZYME INC | Methods of treating cancer |
Aug, 2034
(8 years from now) | |
| US9855275 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US10245269 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US12161645 | EPIZYME INC | Aryl-or heteroaryl-substituted benzene compounds |
Sep, 2031
(5 years from now) | |
| US11491163 | EPIZYME INC | Salt form of a human histone methyltransferase EZH2 inhibitor |
Apr, 2033
(7 years from now) | |
| US10786511 | EPIZYME INC | Method for treating cancer |
Dec, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-835) | Jun 18, 2023 |
| New Indication(I-836) | Jun 18, 2023 |
| New Chemical Entity Exclusivity(NCE) | Jan 23, 2025 |
| Orphan Drug Exclusivity(ODE-299) | Jan 23, 2027 |
| Orphan Drug Exclusivity(ODE-314) | Jun 18, 2027 |
Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient
NCE-1 date: 24 January, 2024
Market Authorisation Date: 23 January, 2020
Dosage: TABLET
More Information on Dosage
TAZVERIK family patents
2. Zydelig patent expiration
Treatment: For the treatment of patients with cll, fl, or sll; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll); Inhibition on pi3k kinase; For the tr...
ZYDELIG's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6800620 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8637533 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8492389 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8138195 | GILEAD SCIENCES INC | Inhibitors of human phosphatidylinositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US6949535 | GILEAD SCIENCES INC | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
Apr, 2021
(4 years ago) | |
| US8865730 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(7 years from now) | |
| USRE44638 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Aug, 2025
(5 months ago) | |
| US10730879 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Mar, 2033
(7 years from now) | |
| US9469643 | GILEAD SCIENCES INC | Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8980901 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta |
May, 2025
(7 months ago) | |
| US9492449 | GILEAD SCIENCES INC | Therapies for hematologic malignancies |
Mar, 2030
(4 years from now) | |
| US9149477 | GILEAD SCIENCES INC | 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta |
May, 2025
(7 months ago) | |
| USRE44599 | GILEAD SCIENCES INC | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
Jul, 2025
(5 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 23, 2019 |
| Orphan Drug Exclusivity(ODE) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-70) | Jul 23, 2021 |
| Orphan Drug Exclusivity(ODE-71) | Jul 23, 2021 |
Drugs and Companies using IDELALISIB ingredient
NCE-1 date: 23 July, 2018
Market Authorisation Date: 23 July, 2014
Dosage: TABLET
How can I launch a generic of ZYDELIG before it's drug patent expiration?
More Information on Dosage
ZYDELIG family patents